Electromyography in Patients on Chronic Pyridostigmine Therapy
| Status: | Recruiting |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 12 - 80 |
| Updated: | 4/21/2016 |
| Start Date: | December 2013 |
| End Date: | February 2017 |
| Contact: | Denise Zeller, RN |
| Email: | denise.zeller@utoledo.edu |
| Phone: | 419-383-6223 |
Electromyography With Repetitive Nerve Stimulation in Patients on Chronic Pyridostigmine Therapy
The investigators are intending to enroll Patients who are chronically treated with
pyridostigmine for the treatment of any medical condition and presenting at the
investigators' outpatient clinics for follow up appointment. Subjects taking pyridostigmine
for the treatment of myasthenia gravis will be excluded. Both adults and children older than
12 years of age will be approached. Those subjects that agree to participate will be asked
to sign an informed consent. For the participation of minors a parental (or guardian)
consent and subject assent will be obtained. Those that participate will answer a few
questions pertaining to their medical history and will then undergo electromyograph (CMAP)
measurement with repetitive stimulation at 2 sites (ulnar nerve at the wrist and the
accessory nerve in the neck). Evoked electromyogram will be recorded on a computer hard
drive. Eight percent or greater decrement in the CMAP response on repetitive stimulation
will be considered positive.
pyridostigmine for the treatment of any medical condition and presenting at the
investigators' outpatient clinics for follow up appointment. Subjects taking pyridostigmine
for the treatment of myasthenia gravis will be excluded. Both adults and children older than
12 years of age will be approached. Those subjects that agree to participate will be asked
to sign an informed consent. For the participation of minors a parental (or guardian)
consent and subject assent will be obtained. Those that participate will answer a few
questions pertaining to their medical history and will then undergo electromyograph (CMAP)
measurement with repetitive stimulation at 2 sites (ulnar nerve at the wrist and the
accessory nerve in the neck). Evoked electromyogram will be recorded on a computer hard
drive. Eight percent or greater decrement in the CMAP response on repetitive stimulation
will be considered positive.
Inclusion Criteria:
- Subjects who have been taking pyridostigmine for the treatment of any condition
Exclusion Criteria:
We found this trial at
1
site
Toledo, Ohio 43699
Principal Investigator: Shashi Bhatt, MD
Phone: 419-383-3556
Click here to add this to my saved trials
